

FACT SHEET



Safyr is advancing a next-generation smart ring built on its proprietary Vascular Impedance Mapping™ (VIM™) technology – a novel approach designed to directly sense arterial dynamics from the finger. Unlike optical wearables that infer cardiovascular metrics indirectly, Safyr's platform is engineered to capture real vascular signals, enabling a new category of precision, cuffless blood pressure monitoring. With foundational intellectual property secured and system engineering underway in partnership with CSEM, 2026 is focused on translating this breakthrough sensing architecture into an integrated, manufacturable device platform.

Milestones Achieved

Research Feasibility Demonstrated: 2025

Safyr completed pilot human feasibility studies evaluating its Vascular Impedance Mapping™ technology in 37 adult volunteers. Preliminary analyses demonstrated strong correlation between ring-derived vascular signals and reference cuff-based blood pressure measurements, supporting continued engineering development and algorithm refinement. These results established the technical foundation for integrated device development and regulatory planning.

Regulatory Pathway Defined: January 2026

Safyr has defined a U.S. regulatory strategy informed by recent 510(k) precedent in cuffless blood pressure monitoring.

The company's clinical and performance validation plans are aligned with ISO 81060-2 standards and recent FDA-cleared wearable blood pressure devices.

Foundational U.S. Patent Allowed: February 2026

Safyr's core U.S. patent covering its Vascular Impedance Mapping™ (VIM™) technology has been allowed by the USPTO, establishing foundational intellectual property protection for its cuffless blood pressure platform. Issuance is pending.

Strategic Engineering Partnership with CSEM: February 2026

Safyr entered into a development collaboration with CSEM (Switzerland), a globally recognized leader in advanced microelectronics and wearable system engineering.

CSEM's involvement supports the technical validation and system architecture development required to bring Safyr's ring-based vascular sensing platform to market.

Clinical Validation Strategy Established: March 2026

Safyr has initiated engagement with an independent U.S. clinical research laboratory to scope pivotal validation testing in support of FDA submission.

The planned study will evaluate device accuracy against reference blood pressure measurements in a diverse adult population.

Upcoming Milestones

System Feasibility Completion with CSEM: Q2 2026

Completion of the engineering feasibility study will define system architecture, performance parameters, and the development roadmap required for full-scale device build.

Integrated Engineering Development Phase: H2 2026

Following completion of the CSEM system feasibility study, Safyr will enter full engineering development, focused on building and optimizing an integrated wearable prototype. This phase will include hardware, firmware, and algorithm integration within the ring form factor, system performance optimization, and preparation for design verification activities in advance of formal clinical validation.

Pivotal Clinical Trial Initiation: Q1 2027

Launch of a controlled clinical validation study to demonstrate blood pressure accuracy in accordance with international standards.

Targeted FDA 510(k) Submission: Late 2027

Submission of Safyr's cuffless blood pressure ring for U.S. regulatory clearance.